Other approaches to target the more common KRAS mutations (eg. G12D—MRTX1133 [49]), pan-(K) RAS inhibitors (eg. BI- 2865, RMC- 6236 [50, 51]) and inhibitors for the RAS guanine nucleotide exchange factor SOS1 [52] are investigated at preclinical/first-in-human stages in pan-cancer models. Here, KRAS is linked to cancer.